Czech drug-discovery biotech developing proprietary small-molecule inhibitors of casein kinase 1 (CK1), with a pan-isoform approach targeting CK1α, CK1δ and CK1ε
Czech drug-discovery biotech developing proprietary small-molecule inhibitors of casein kinase 1 (CK1), with a pan-isoform approach targeting CK1α, CK1δ and CK1ε. Its preclinical pipeline aims to overcome resistance to cancer therapies, including in AML, melanoma and pancreatic cancer, with additional solid-tumor and CNS indications under development or partnership.